🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Atopic Dermatitis (AD)

A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema) NCT07355075Phase 2, Phase 31 site📍 Irving Turn Therapeutics · Tests: GX-03, Vehicle Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis NCT07298395Phase 232 sites📍 Birmingham📍 Hot Springs📍 Beverly Hills Enveda Therapeutics · Tests: ENV-294, Placebo A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Moderate to Severe Atopic Dermatitis (AD) NCT07239947Phase 110 sites📍 Hefei📍 Wuhu📍 Beijing Bambusa Therapeutics · Tests: BBT001, Placebo Effect of an Emollient Cream Containing a Milk Bioactive Peptide on Clinical Signs, Pruritus and Bacterial Colonization of Mild Atopic Dermatitis Skin Lesions in Pediatric Population NCT07259343NA1 site📍 Aguascalientes Universidad Autónoma de Aguascalientes · Tests: glycomacropeptide, emollient cream Birth Cohort: Development of IgE Autoantibodies in Newborns With (High Risk of) Atopic Dermatitis NCT07316465NA1 site📍 Jette Universitair Ziekenhuis Brussel · Tests: Development of atopic dermatitis with/without IgE autoantibodies Evaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic Dermatitis NCT07042126Phase 33 sites📍 Beijing📍 Jinhua📍 Nanchang Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · Tests: 611, Matching placebo Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis NCT06982352Phase 13 sites📍 Fargo📍 Dallas📍 Amman LAPIX Therapeutics Inc. · Tests: LPX-TI641, Placebo SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY) NCT07021495n/a8 sites📍 Nijmegen📍 Maastricht📍 Amsterdam Leiden University Medical Center A Study to Learn About the Study Medicine (Called Cibinqo) in People With Atopic Dermatitis NCT05391061n/a1 site📍 Seoul Pfizer · Tests: Abrocitinib A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD) NCT06808477Phase 114 sites📍 Irvine📍 New York📍 The Bronx Bambusa Therapeutics · Tests: BBT001, Placebo Monitoring Pregnancy and Infant Outcomes Following Tralokinumab Exposure During Pregnancy in the US and Canada - PROTECT NCT05938478n/a1 site📍 La Jolla University of California, San Diego · Tests: Tralokinumab A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis NCT07558668Phase 114 sites📍 Arkansas City📍 Fremont📍 Plainfield Sitryx Therapeutics Ltd · Tests: SYX-5219 Oral Capsule CorEvitas International Adolescent Atopic Dermatitis (AD) Drug Safety and Effectiveness Registry NCT06238765n/a1 site📍 Waltham CorEvitas A Long-term Safety and Efficacy Study Evaluating CM512 in Atopic Dermatitis. NCT07230483Phase 21 site📍 Beijing Keymed Biosciences Co.Ltd · Tests: CM512 Evaluation of Efficacy and Safety of Oral Roflumilast for Treatment of Moderate to Severe Atopic Dermatitis in Patients Aged 12 Years and Older: A Pilot Study NCT07297602Phase 21 site📍 Al Mansurah Nora Mohamed Abdelrazik · Tests: Oral roflumilast A Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-002-158 Tablets in Chinese Adult Subjects With Atopic Dermatitis NCT06931990Phase 1, Phase 21 site📍 Beijing Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. · Tests: LT-002-158 tablets Evaluation of 611 in Chinese Children With Moderate to Severe Atopic Dermatitis(AD) NCT07767253Phase 35 sites📍 Beijing📍 Beijing📍 Guangzhou Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · Tests: 611, 611, Matching placebo Phase II Clinical Study to Evaluate the Efficacy and Safety of LT-002-158 Tablets in Adult Patients With Moderate-to-Severe Atopic Dermatitis NCT07895615Phase 21 site📍 Hangzhou Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. · Tests: LT-002-158, Placebo Phase 2 Randomized Double-blind Study to Assess Topical Zabalafin Hydrogel Vs Vehicle in Mild to Moderate AD. NCT06855745Phase 212 sites📍 Brookvale📍 Darlinghurst📍 Kogarah Alphyn Biologics · Tests: zabalafin A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis. NCT05689151n/a30 sites📍 Amiens📍 Besançon📍 Bezannes Pfizer · Tests: Abrocitinib A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis NCT07235384Phase 112 sites📍 Woolloongabba📍 Carlton📍 Beijing Zai Lab (Shanghai) Co., Ltd. · Tests: ZL-1503, Placebo, ZL-1503, Placebo Effect of Partially Hydrolyzed Formula With Synbiotics on Skin Barrier Function NCT06943469NA25 sites📍 Bruges📍 Brussels📍 Namur Société des Produits Nestlé (SPN) · Tests: Test formula, Control formula Skin Microbial Ecology in Atopic Dermatitis NCT04170244n/a1 site📍 Rochester University of Rochester · Tests: AD subject visit sampling procedures, PS subject visit sampling procedures, Healthy control visit sampling procedures Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD NCT07441395Phase 21 site📍 South San Francisco Corvus Pharmaceuticals, Inc. · Tests: Soquelitinib, Placebo A Phase III Study of GS101 Injection to Dupixent® NCT07386743Phase 31 site📍 Shenyang Jiangsu Genscend Biopharmaceutical Co., Ltd · Tests: GS101 injection, DUPIXENT® Reflectance Confocal Microscopy Evaluation of Skin Structure of Patients With Atopic Dermatitis Under Nemolizumab NCT07730788n/a1 site📍 Romans-sur-Isère Hôpitaux Drôme Nord Herbal Ointment in Treating Atopic Dermatitis Topically NCT06850311Phase 2, Phase 31 site📍 New Taipei City En Chu Kong Hospital · Tests: herbal ointment, Placebo A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab NCT06524635Phase 22 sites📍 Sacramento📍 Ann Arbor AbbVie · Tests: Lutikizumab A First-in-human Study to Investigate Single Doses of DCY636 in Healthy Volunteers and Multiple Doses in Participants With Moderate to Severe Atopic Dermatitis NCT07604324Phase 11 site📍 Fukuoka Novartis Pharmaceuticals · Tests: DCY636, Placebo Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease NCT07455578Phase 12 sites📍 Charlestown📍 Birtinya Seismic Therapeutic AU Pty Ltd · Tests: S-4321
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy